Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency ratios demonstrate a notable shift in the company’s financial leverage over the observed period. Initially, the ratios exhibited relative stability, but a clear trend of increasing leverage emerges in the later quarters, particularly from the end of 2023 through the available projections into 2025.
- Debt to Equity Ratio
- The debt to equity ratio began at 4.51 and fluctuated between approximately 4.35 and 4.98 through the first three quarters of 2022, decreasing to 3.67 by the end of the year. It remained relatively stable in the first half of 2023, but then began a significant upward trajectory. By the end of 2024, the ratio reached 20.19, and projections for 2025 indicate a substantial increase to 49.22. This indicates a rapidly increasing reliance on equity financing relative to debt.
- Debt to Capital Ratio
- The debt to capital ratio remained consistently around 0.82 to 0.83 for the majority of the period, with a slight increase to 0.85 by the end of 2022. This ratio continued to rise gradually, reaching 0.98 by the end of 2024. Projections for 2025 suggest this trend will continue, with the ratio reaching 1.04 and then 1.05, indicating that debt is approaching 100% of the company’s capital structure.
- Debt to Assets Ratio
- The debt to assets ratio showed a slight downward trend from 0.51 in March 2022 to 0.44 by December 2022. This ratio remained stable at 0.45 for several quarters before increasing to 0.50 by the end of 2024. The projections for 2025 suggest continued stability at 0.51. While relatively stable, the increase in the latter part of the period suggests a growing proportion of assets financed by debt.
- Financial Leverage Ratio
- The financial leverage ratio exhibited a similar pattern to the debt to equity ratio. It started at 8.80 and fluctuated before increasing significantly from 13.00 at the end of 2022 to 40.65 by the end of 2024. Projections for 2025 indicate a dramatic increase to 95.89. This substantial rise suggests a considerable amplification of both potential gains and losses due to the use of debt financing.
In summary, while initial solvency ratios indicated a manageable level of debt, the trend over the observed period reveals a substantial and accelerating increase in financial leverage. This shift warrants further investigation to understand the underlying drivers and potential implications for the company’s financial risk profile.
Debt Ratios
Debt to Equity
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||
| Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio exhibits a notable and escalating trend over the observed period. Initially, the ratio fluctuated between 4.35 and 4.98 from March 2022 to June 2022, indicating a relatively stable, though leveraged, capital structure. However, a consistent upward trajectory began in late 2022 and accelerated through 2023 and into 2024.
- Initial Stability (Mar 31, 2022 – Jun 30, 2022)
- The debt to equity ratio remained within a narrow range, suggesting a consistent reliance on debt financing relative to equity. Values of 4.51, 4.98, 4.35, and 3.67 were recorded during this period.
- Increasing Leverage (Sep 30, 2022 – Dec 31, 2023)
- From September 2022 onwards, the ratio began to increase, moving from 4.35 to 5.73 by the end of 2023. This indicates a growing proportion of debt relative to equity, potentially reflecting increased borrowing or a decrease in equity.
- Rapid Escalation (Mar 31, 2024 – Dec 31, 2025)
- The most significant change occurred from March 2024 onward. The ratio increased dramatically, reaching 9.24 in March 2024, 10.42 in June 2024, 11.78 in September 2024, and peaking at 20.19 in December 2024. This substantial increase suggests a significant shift in the company’s capital structure, with a much heavier reliance on debt. The trend continues into 2025, with the ratio reaching 49.22 in March 2025, and then transitioning to negative equity values, resulting in undefined ratios for the remaining periods.
The concurrent decline in stockholders’ equity, particularly evident from March 2024, is a key driver of the escalating debt to equity ratio. The transition to a negative equity position in June 2025 further exacerbates the ratio, indicating a substantial imbalance between liabilities and owner’s investment. The increasing ratio suggests a heightened level of financial risk, as the company is increasingly financed by debt rather than equity.
Debt to Capital
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||
| Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio exhibits a generally increasing trend over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicate a relatively stable ratio in the earlier part of the period, followed by a more pronounced upward movement in the latter half.
- Initial Stability (Mar 31, 2022 – Dec 31, 2022)
- From March 31, 2022, to December 31, 2022, the debt to capital ratio fluctuated between 0.79 and 0.83. This suggests a period of relatively consistent financial leverage. Total debt decreased from 73,474 to 63,271 US$ millions, while total capital also decreased, from 89,757 to 80,525 US$ millions, resulting in a slight decrease in the ratio over this timeframe.
- Increasing Leverage (Mar 31, 2023 – Dec 31, 2024)
- Beginning in March 31, 2023, the ratio began a consistent upward trend, increasing from 0.82 to 0.95 by December 31, 2024. This indicates a growing reliance on debt financing relative to capital. Both total debt and total capital decreased during this period, but the decrease in total capital was more substantial, driving the ratio higher.
- Continued Increase and Peak (Mar 31, 2025 – Dec 31, 2025)
- The upward trend continued into 2025, with the debt to capital ratio reaching 0.98 in March 31, 2025, 1.00 in June 30, 2025, and peaking at 1.05 in December 31, 2025. This represents the highest level of financial leverage observed throughout the analyzed period. Total debt decreased slightly from 69,889 to 67,496 US$ millions, but total capital experienced a more significant decrease, from 71,309 to 64,226 US$ millions, accelerating the ratio’s increase.
- Overall Trend
- The overall trend demonstrates a shift towards increased financial leverage. While the initial period showed relative stability, the latter portion of the period is characterized by a consistent and accelerating increase in the debt to capital ratio. This suggests a potential change in the company’s financing strategy or capital structure.
The observed increases in the debt to capital ratio warrant further investigation to understand the underlying drivers and potential implications for the company’s financial risk profile.
Debt to Assets
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||
| Current portion of long-term debt and finance lease obligations | |||||||||||||||||||||
| Long-term debt and finance lease obligations, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio for the analyzed period demonstrates a generally decreasing trend followed by a recent increase. Initially, the ratio fluctuated around 0.51 before exhibiting a consistent decline through the end of 2022. Subsequently, the ratio stabilized and then increased in early 2024, before decreasing slightly again.
- Initial Trend (Mar 31, 2022 – Dec 31, 2022)
- The debt-to-assets ratio began at 0.51 in March 2022 and decreased to 0.44 by December 2022. This indicates a reduction in the proportion of assets financed by debt during this period. The decline suggests improved solvency or a strategic shift towards equity financing, or potentially asset growth outpacing debt accumulation.
- Stabilization and Subsequent Increase (Mar 31, 2023 – Dec 31, 2023)
- From March 2023 through December 2023, the ratio remained relatively stable, fluctuating between 0.44 and 0.46. This suggests a period of consistent capital structure management. However, the ratio increased to 0.50 in March 2024, indicating an increase in debt relative to assets.
- Recent Fluctuations (Mar 31, 2024 – Dec 31, 2025)
- Following the increase in March 2024, the ratio remained at 0.50 for three consecutive quarters before decreasing to 0.51 in March 2025 and then decreasing slightly to 0.50 by December 2025. This recent fluctuation suggests potential short-term adjustments in the company’s financing strategy or asset base. The ratio remains within the range observed earlier in the period, but the recent increase warrants monitoring.
- Overall Observation
- Throughout the analyzed period, the debt-to-assets ratio remained between 0.44 and 0.51. While a general downward trend was observed initially, the ratio has stabilized and recently shown a slight increase. The company’s solvency position appears generally healthy, but the recent changes in the ratio should be considered in a broader financial context.
Financial Leverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
The financial leverage ratio exhibits a pronounced upward trend over the observed period, indicating an increasing reliance on debt financing relative to equity. Initial values demonstrate a relatively stable leverage position, but a significant shift occurs beginning in the latter half of 2022 and accelerating through 2025.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- Financial leverage fluctuates between 8.04 and 9.77 during this period. While some variation exists, the ratio remains within a relatively narrow range, suggesting a consistent, though moderately leveraged, capital structure. A slight decrease is observed from March 2022 to December 2022.
- Increasing Leverage (Mar 31, 2023 – Dec 31, 2023)
- The ratio begins to climb more noticeably, increasing from 10.14 to 13.00. This suggests a deliberate or necessary increase in debt financing. The trend indicates a growing dependence on borrowed funds.
- Rapid Escalation (Mar 31, 2024 – Dec 31, 2025)
- A dramatic increase in financial leverage is evident. The ratio escalates from 18.59 in March 2024 to 95.89 in March 2025, and continues to rise, reaching a value of -3.270 in December 2025. This substantial increase suggests a significant shift in the company’s capital structure, potentially driven by substantial debt accumulation or a significant decline in stockholders’ equity. The negative equity values in the final periods further exacerbate the concern.
The concurrent decline in stockholders’ equity, particularly evident from March 2023 onwards, contributes significantly to the increasing leverage ratio. The movement into negative equity in the latter periods is a critical development, indicating that liabilities exceed assets. This trend warrants further investigation to understand the underlying causes and potential implications for the company’s financial health.
The observed pattern suggests a progressively riskier financial position. While moderate leverage can be beneficial, the magnitude of the increase, coupled with the decline in equity, raises concerns about the company’s ability to meet its long-term obligations.